By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genomic Health today said that strong sales of its flagship Oncotype DX breast cancer recurrence test drove a 12 percent increase in third-quarter revenue to $52.1 million from $46.3 million in the comparable period of 2010.

The Redwood City, Calif.-based firm just missed analysts' consensus revenue estimate of $52.3 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.